Compare Stocks: QURE, IMVT, KNSA, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.25B	0.84	1.61 million shs	1.49 million shs
KNSA Kiniksa Pharmaceuticals International	$79.78 +1.3%	$77.57	$35.20 ▼ $82.94	$6.14B	0.04	553,826 shs	430,275 shs
QURE uniQure	$22.59 +0.2%	$41.57	$8.73 ▼ $71.50	$1.57B	1.06	3.49 million shs	2.05 million shs
RYTM Rhythm Pharmaceuticals	$90.78 +1.3%	$103.95	$74.50 ▼ $122.20	$6.14B	2.01	805,712 shs	1.41 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	+0.69%	-9.37%	-21.37%	-23.27%	+89.49%
KNSA Kiniksa Pharmaceuticals International	+1.31%	+5.26%	+1.60%	+25.76%	+108.25%
QURE uniQure	+0.22%	-3.71%	-50.89%	-47.01%	-62.33%
RYTM Rhythm Pharmaceuticals	+1.27%	-2.21%	-10.17%	-16.25%	-9.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.25B	0.84	1.61 million shs	1.49 million shs
KNSA Kiniksa Pharmaceuticals International	$79.78 +1.3%	$77.57	$35.20 ▼ $82.94	$6.14B	0.04	553,826 shs	430,275 shs
QURE uniQure	$22.59 +0.2%	$41.57	$8.73 ▼ $71.50	$1.57B	1.06	3.49 million shs	2.05 million shs
RYTM Rhythm Pharmaceuticals	$90.78 +1.3%	$103.95	$74.50 ▼ $122.20	$6.14B	2.01	805,712 shs	1.41 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	+0.69%	-9.37%	-21.37%	-23.27%	+89.49%
KNSA Kiniksa Pharmaceuticals International	+1.31%	+5.26%	+1.60%	+25.76%	+108.25%
QURE uniQure	+0.22%	-3.71%	-50.89%	-47.01%	-62.33%
RYTM Rhythm Pharmaceuticals	+1.27%	-2.21%	-10.17%	-16.25%	-9.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.58	Moderate Buy	$44.00	44.40% Upside
KNSA Kiniksa Pharmaceuticals International	2.89	Moderate Buy	$93.14	16.75% Upside
QURE uniQure	2.75	Moderate Buy	$53.73	137.84% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.89	55.20% Upside

Current Analyst Ratings Breakdown

Latest QURE, IMVT, KNSA, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$155.00 ➝ $159.00
10/5/2026	QURE uniQure	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$60.00 ➝ $28.00
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	QURE uniQure	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$65.00 ➝ $48.00
9/30/2026	QURE uniQure	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$46.00 ➝ $31.00
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$87.00
9/29/2026	QURE uniQure	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$75.00
9/29/2026	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.19	$0.80 per share	99.21	$7.44 per share	10.72
QURE uniQure	$18.67M	83.92	N/A	N/A	$3.19 per share	7.08
RYTM Rhythm Pharmaceuticals	$189.76M	32.78	N/A	N/A	$2.08 per share	43.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	82.25	38.54	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest QURE, IMVT, KNSA, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7165	N/A	N/A	N/A	$85.46 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3699	N/A	N/A	N/A	$259.65 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	7.27	7.27
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
QURE uniQure	0.15	10.01	10.01
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KNSA Kiniksa Pharmaceuticals International	53.95%
QURE uniQure	78.83%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.90%
KNSA Kiniksa Pharmaceuticals International	51.98%
QURE uniQure	4.65%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

QURE, IMVT, KNSA, and RYTM Headlines

Recent News About These Companies

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

October 9 at 3:44 AM | finance.yahoo.com

RBC raises target for Rhythm Pharmaceuticals stock to USD 159

October 8 at 10:43 PM | ad-hoc-news.deA

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67 According to Brokerages

September 30, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67

September 30, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

Rhythm Pops on Health Canada Nod

September 23, 2026 | baystreet.ca

Rhythm Pharmaceuticals, Inc. Announces Health Canada Approval Of IMCIVREE (Setmelanotide) For Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With ...

September 23, 2026 | marketscreener.comM

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

September 23, 2026 | streetinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with ...

September 22, 2026 | markets.businessinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

September 22, 2026 | globenewswire.com

325,470 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Bank of America Corp DE

September 22, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

September 17, 2026 | marketscreener.comM

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

September 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

September 15, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners

September 14, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IMVT, KNSA, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

$30.47 +0.21 (+0.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$30.48 +0.01 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$79.78 +1.03 (+1.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$79.79 +0.01 (+0.01%)

As of 10/9/2026 07:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

uniQure NASDAQ:QURE

$22.59 +0.05 (+0.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$22.54 -0.05 (-0.22%)

As of 10/9/2026 07:32 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Rhythm Pharmaceuticals NASDAQ:RYTM

$90.78 +1.14 (+1.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$90.80 +0.02 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, IMVT, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, IMVT, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, IMVT, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IMVT, KNSA, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

uniQure NASDAQ:QURE

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, IMVT, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, IMVT, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, IMVT, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IMVT, KNSA, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

uniQure NASDAQ:QURE

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools